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ABSTRACT 
Aim of this study is to review the evidence of different therapy approach, to highlight the 
areas of major concern, and to suggest specific oral surgery treatment for patients on new oral 
anticoagulants.  
A Medline and an extensive hand search were performed on English-language 
publications beginning in 1971 till now. The pertinent literature and clinical protocols of 
hospital dentistry departments have been extensively reviewed, presented and discussed.  
Several evolving clinical practices in the last years have been detected: anticoagulants are 
generally not discontinued; oral surgery is performed despite laboratory values showing 
significant bleeding tendency; new effective local hemostatic modalities are used to prevent 
bleeding; Patients at risk are referred to hospital-based clinics.  
The management of oral surgery procedures on patients treated with new anticoagulants 
should be influenced by several factors: laboratory values, extent and urgency of the 
intervention, treating physician’s recommendation, available facilities, dentist expertise, and 
patient’s oral, medical, and general condition. 
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Introduction 
Thrombosis is the formation, from the components of blood, of an abnormal mass within the 
vascular system. It involves the interaction of vascular, cellular, and humoral factors within a 
flowing stream of blood. Thrombosis and the complicating emboli that can result are among the 
most important causes of sickness and death in developed countries. Thrombosis is of greater 
overall clinical importance in terms of morbidity and mortality than all of the hemorrhagic disorders 
combined. Excessive activation of coagulation or inhibition of anticoagulant mechanisms may 
result in hypercoagulability and thrombosis. Injury to the vessel wall, alterations in blood flow, and 
changes in the composition of blood are major factors leading to thrombosis [7]. 
The dentist today is seeing increased numbers of patients with chronic medical illnesses. 
Among these patients are those that are being treated with anticoagulant drugs or antiplatelet agents 
to prevent venous or arterial thrombosis. A major concern in the management of dental patients 
taking antithrombotic agents is the potential for excessive bleeding after invasive dental procedures 
[5]. The pathologic basis for arterial thrombosis involves atherosclerotic vascular disease associated 
with platelet thrombi. Thrombin is a major mediator in this type of thrombosis. Drug therapy for 
arterial thrombi involves agents with antithrombin and antiplatelet activity. Venous thrombi usually 
occur in the presence of a normal vessel wall, with stasis or hypercoagulability being the major 
predisposing factors. Drugs that prevent thrombin formation or lyse fibrin clots are the major agents 
used to treat venous thrombi. 
Aim of this study is to review the evidence of different therapy approach, to highlight the 
areas of major concern, and to suggest specific oral surgery treatment for patients on new oral 
anticoagulants.  
A Medline and an extensive hand search were performed on English-language publications 
beginning in 1971 till now. The pertinent literature and clinical protocols of hospital dentistry 
departments have been extensively reviewed, presented and discussed.  
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Oral anticoagulants – withdraw or continuing  
The term oral anticoagulant (OAC) refers to oral vitamin K antagonists, including mainly 
sodium warfarin (the most widely used agent in Anglo-Saxon countries) and acenocoumarol 
(widely used in some countries of Europe) [11].  
Oral anticoagulants are a group of drugs used to treat many cardiovascular diseases, such as in 
the prophylaxis of systemic embolism (whose risk is increased in patients with atrial fibrillation or 
have undergone orthopaedic surgery). The vitamin K antagonists, among which are warfarin and 
acenocoumarol, have low therapeutic index as its pharmacological management is difficult and 
need continuous monitoring, also have multiple interactions with other drugs and food. Many of the 
patients being treated with warfarin have an inadequate anticoagulation [2].  
The oral and maxillofacial surgeons are frequently asked to manage patients who are 
receiving oral anticoagulants. The goal of treatment is to minimize the risk of hemorrhage while 
continuing to protect the patient against thromboembolism formation. The ordinary treatment 
includes the interruption of anticoagulant therapy for oral surgery interventions to prevent 
hemorrhage. However, this practice may logically increase the risk of a potentially life-threatening 
thromboembolism. Thus, this issue is still controversial [5]. 
Assael [3] said that the hemostasis care of the oral anticoagulated patients is a shared 
responsibility and oral and maxillofacial surgeons, and the hematology/coagulation team huddle to 
determine the steps.  
 
New oral anticoagulants 
New oral anticoagulants, with distinctly different mechanisms of action, are 
poised to replace the VKAs and have the potential to dramatically change the way 
we manage patients at risk for venous and arterial thromboembolic disease. In 
contrast to the vitamin K antagonist (VKAs), which target an enzyme in the 
vitamin K pathway that leads to the reduction of the functional levels of 
factors II, VII, IX, and X, many of the new agents rely on targeting a 
particular coagulation factor and directly inhibiting it.  
Figure 1 identifies a number of new agents and their target factor. This 
discussion will focus on three such  agents that are most advanced in development 
and likely to be the first to reach market in the United States. 
 
Figure 1. New oral anticoagulants under development that target factor IIa and factor Xa. 
(Adapted from reference 1) 
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Several evolving clinical practices in the last years have been detected: anticoagulants are 
generally not discontinued; oral surgery is performed despite laboratory values showing significant 
bleeding tendency; new effective local hemostatic modalities are used to prevent bleeding; Patients 
at risk are referred to hospital-based clinics [1].  
The patient on Pradaxa® (Dabigatran) may need interruption of therapy for dental work, a 
medical procedure such as colonoscopy, or minor or major surgical procedure. As to when exactly 
to take the last dose of Pradaxa® before the procedure depends on (a) what type of procedure is 
planned and how much bleeding to expect with it, and (b) whether the patient is at high or low risk 
for thrombosis if he/she is off anticoagulants for some period of time [4]. 
 
Table 1. Pharmacologic Features of Dabigatran Etexilate, Rivaroxaban, and Apixaban 
 Dabigatran Etexilate Apixaban Rivaroxaban 
Target Thrombin Factor Xa Factor Xa 
Prodrug Yes No No 
Dosing Fixed, once daily Fixed, twice daily Fixed, once daily 
Bioavailability (%) 6 50 80 
Monitoring No No No 
Half-life (h) 12-14* 12.7 7-11 
Renal clearance (%) 80 25 65 
Interactions P-gp inhibitors
**









*In healthy volunteers, 14-17 hours in patients undergoing major orthopaedic surgery. 
**P-glycoprotein (P-gp) inhibitors include verapamil, clarithromycin, and quinidine.  
Quinidine is contraindicated in patients receiving dabigatran. 
†
Cytochrome P450 (CYP) 3A4 inhibitors include ketoconazole, macrolide antibiotics, and protease 
inhibitors. 
 
Dabigatran eteksilate (Pradaxa) with ATS cod B01AE07 (classification - antithrombotic)  
Boehringer Ingelheim  (caps. 75mg и 110 mg) is registered in Macedonia, Serbia and Bulgaria. 
Rivaroxaban is not registered in the region. 
 
Table2. Guide to the discontinuation of Pradaxa® before procedures or surgeries  





Timing of Discontinuation Prior to Procedure (Minimum) 
Standard Risk of Bleeding High Risk of Bleeding* 
> 80 13 (11 – 22) 24 hours 2 – 4 days 
50 – 80 15 (12 – 34) 24 hours 2 – 4 days 
30 – 50 18 (13 – 23) > 48 hours > 4 days 
< 30 27 (22 – 35) 48 – 120 hours > 5 days 
* 
Examples: heart surgery, neurosurgery (brain, spinal cord, nerves), abdominal or surgery involving 
major organs; or procedures requiring guaranteed no bleeding (i.e., spinal anesthesia), or when 
additional risk factors for bleeding are present (low blood platelets, bleeding disorder, previous major 
bleeding, etc.). 
 
Dental Procedures and Bridging Therapy 
Depending on the existing thromboembolic risk, the American Heart Association / American 
College of Cardiology Foundation Guide to Warfarin Therapy recommends different heparin 
management regimens for the patients with moderate, high and low thromboembolic risk. In 
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general, heparins are not reintroduced before 12 hours post-surgery and dosing is postponed for 
longer periods in the case of evidence of bleeding [9]. 
Most patients treated with standard heparin are hospitalized and will be placed on warfarin 
once discharged. Dental emergencies in these hospitalized patients should be treated as 
conservatively as possible, avoiding invasive procedures. Consultation with the patient’s physician 
is recommended. In contrast, patients undergoing hemodialysis are administered heparin in an 
outpatient setting. Since the half-life of heparin is only 1 to 2 hours,1 these patients can safely 
receive invasive dental treatment.the day after dialysis. 
Alternatively, the attending physician may give permission for hemodialysis to be performed 
without heparin when major surgical procedures are required on the day of dialysis.  
Many dental procedures can be done on full dose anticoagulation. Detailed recommendations 
as to which dental procedures can be done on full dose anticoagulation (teeth cleaning, root canal, 
one or two teeth extractions) and for which the anticoagulant level needs to be reduced have been 
published. A similar approach can likely be taken in patients on Pradaxa®. However, it is also easy 
to tell the patient not to take his/her evening dose of Pradaxa® on the day before the procedure and 
not to take the morning dose on the day of the dental procedure; and then to restart the evening of 
the day of the procedure. However, individualized recommendations need to be given [8, 10]. 
 A review by Wahl [12] found little to no risk of significant bleeding 
following dental surgical procedures in patients with a PT of 1.5 to 2 times 
normal. Wahl [12] also reported evidence that there was little risk of bleeding 
complications even if the PT is up to 2.5 times normal, and a greater risk of 
adverse outcome is associated with stopping anticoagulation.  
Life threatening or major bleeding in patients who need high-risk surgery is avoided by 
stopping oral anticoagulants with or without bridging therapy. The Food and Drug Administration 
has not approved bridging therapy with LMWH in patients with prosthetic heart valves, and UFH is 
frequently recommended for bridging therapy in these high-risk patients who develop arterial 
thromboembolism. 
Bridging with UFH or LMWH is done to shorten the interval of sub therapeutic 
anticoagulation while waiting for the reversal of oral anticoagulation. For patients with a low risk of 
thromboembolism, bridging is not recommended because the efficacy of bridging with UFH and 
LMWH does not outweigh the risk of postoperative bleeding [6]. During the past 20 years, the 
approval of anticoagulants such as low-molecular-weight heparins (LMWHs), indirect factor Xa 
inhibitors and direct thrombin inhibitors has signaled a growing interest in antithrombotic 
compounds that have relatively discrete targets within the coagulation pathway. 
Patients with a low risk of thromboembolism can stop the oral anticoagulant and restart it 
after the surgery. Stopping oral anticoagulant and bridging is not recommended for procedures for 
which major bleeding is not likely to develop.  
 
Conclusion 
The currently available anticoagulant agents all target thrombin or FXa, either indirectly or 
directly. Thrombin is a logical target because of its multiple roles in coagulation. 
The management of oral surgery procedures on patients treated with new anticoagulants 
should be influenced by several factors: laboratory values, extent and urgency of the intervention, 
treating physician’s recommendation, available facilities, dentist expertise, and patient’s oral, 
medical, and general condition. 
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